As outlined in this review, recent clinical trials of advanced therapeutic candidates, including GLP-1R agonists, have provided hope that breakthrough pharmacological obesity treatments may be possible. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.